MIV subsidiary SagaX speeds development of implant for stroke prevention

By Lisa Kerner

Erie, Pa., March 10 - MIV Therapeutics Inc. said it has accelerated development of a novel stroke-preventing implantable device for surgical patients.

The Aortic Embolic Protection Device is being developed by MIV's wholly owned subsidiary, SagaX Inc., and may be ready for clinical use within 14 months, according to a company news release.

MIV said the proprietary filter/deflector device is designed to prevent cardioembolic stroke following heart surgery by diverting particles in the bloodstream away from the brain. The device is inserted during surgery and can be removed at the end of the procedure.

The occurrence of significant cardioembolic stroke following surgery is estimated at 1% to 4%, MIV said.

The global market for implantable stroke-prevention devices is expected to grow into a $500 million to $1 billion market in the next few years, according to the release.

SagaX, located in Herzlyia, Israel, develops biomedical technology, including embolic protection devices for the prevention of strokes.

MIV is based in Vancouver, B.C., and develops biocompatible coatings for cardiovascular stents and other implantable medical devices.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.